Eyegate Pharmaceuticals, Inc. (EYEG) Given a $6.00 Price Target by HC Wainwright Analysts
HC Wainwright set a $6.00 target price on Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) in a report published on Wednesday. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.
Separately, Noble Financial reiterated a buy rating on shares of Eyegate Pharmaceuticals in a research note on Friday, May 19th.
Shares of Eyegate Pharmaceuticals (NASDAQ:EYEG) opened at 1.14 on Wednesday. The firm has a 50-day moving average price of $1.34 and a 200-day moving average price of $1.88. Eyegate Pharmaceuticals has a 52 week low of $1.11 and a 52 week high of $3.90. The firm’s market capitalization is $12.40 million.
Eyegate Pharmaceuticals (NASDAQ:EYEG) last released its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.39) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.39). The company had revenue of $0.19 million during the quarter, compared to the consensus estimate of $0.22 million. Eyegate Pharmaceuticals had a negative return on equity of 670.92% and a negative net margin of 1,618.38%. On average, equities analysts expect that Eyegate Pharmaceuticals will post ($0.92) earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was first reported by Daily Political and is the property of of Daily Political. If you are reading this article on another domain, it was copied illegally and reposted in violation of U.S. & international trademark and copyright laws. The correct version of this article can be read at https://www.dailypolitical.com/2017/08/06/eyegate-pharmaceuticals-inc-eyeg-given-a-6-00-price-target-by-hc-wainwright-analysts.html.
Eyegate Pharmaceuticals Company Profile
Eyegate Pharmaceuticals, Inc is a clinical-stage specialty pharmaceutical company. The Company is focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye. The Company’s lead product, EGP-437, incorporates a reformulated topically active corticosteroid, dexamethasone phosphate, which is delivered into the ocular tissues through its drug delivery system, the EyeGate II Delivery System.
Receive News & Ratings for Eyegate Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyegate Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.